- Home
- KODK vs AVTX Comparison
KODK vs AVTX Comparison
Compare KODK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KODK | AVTX |
|---|---|---|
| Founded | 1880 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.9M | 982.5M |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KODK | AVTX |
|---|---|---|
| Price | $9.15 | $19.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $40.57 |
| AVG Volume (30 Days) | ★ 899.1K | 710.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,114,000,000.00 | $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $5.78 | $9.54 |
| 52 Week High | $14.87 | $24.27 |
Technical Indicators
Market Signals| Indicator | KODK | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 46.41 |
| Support Level | $9.13 | $17.40 |
| Resistance Level | $10.20 | $18.95 |
| Average True Range (ATR) | 0.35 | 0.83 |
| MACD | -0.11 | -0.16 |
| Stochastic Oscillator | 28.86 | 4.80 |
Price Performance
Historical ComparisonAbout KODK Eastman Kodak Company
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.